GlobeNewswire by notified

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates


BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first quarter of 2024 ending March 31, 2024.

Roluperidone NDA Update

On February 27, 2024, the Company announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to its New Drug Application (NDA) for roluperidone (f/k/a MIN-101) for the treatment of negative symptoms in patients with schizophrenia. The Company is in discussions with the FDA regarding the issues and clinical deficiencies raised in the CRL.

Phase 1b Clinical Trial (MIN-101C18)

In the first quarter of 2024, the Company completed a clinical trial initiated in October 2023 to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of the co-administration of roluperidone and olanzapine in adult subjects with moderate to severe negative symptoms of schizophrenia. This clinical trial (NCT06107803) was designed to investigate the pharmacodynamic and pharmacokinetic effects and safety of the concomitant therapy of roluperidone with an established and widely used antipsychotic. Of the 17 patients enrolled, 13 completed all 17 days of daily dosing of roluperidone at 64 mg. No new safety signals were observed during the study with few treatment-emergent adverse events (TEAEs), most of which were mild and all resolved without sequelae. No emergent clinically significant electrocardiogram or laboratory abnormalities were observed during the study. There was no symptomatic worsening during the administration of roluperidone alone (7 days) or when administered in combination with olanzapine at 10 mg (10 days). 

The study demonstrated that pharmacokinetic interactions between the two drugs were not relevant.

First Quarter 2024 Financial Results

  • Research and development (R&D) expense: For the three months ended March 31, 2024 and 2023, R&D expense was $4.2 million and $2.7 million, respectively. R&D expense was higher versus the prior year period primarily due to costs associated with the FDA’s review of the Company’s NDA and the conduct of the MIN-101C18 study.
  • General and administrative (G&A) expense: For the three months ended March 31, 2024 and 2023, G&A expense was $2.5 million and $2.7 million, respectively. G&A expense was lower versus the prior year period primarily due to lower professional service fees.
  • Non-cash interest expense: For the three months ended March 31, 2024 and 2023, non-cash interest expense for the sale of future royalties was $2.3 million and $2.0 million, respectively. The increase versus the prior year period was primarily due to the amortization of non-cash interest expense for the difference between the balance of the liability related to the sale of future royalties and the estimated amount of future royalties to be received over the royalty period.
  • Net loss: Net loss was $8.6 million for the three months ended March 31, 2024, or net loss per share of $1.13 basic and diluted, as compared to net loss of $7.0 million for the three months ended March 31, 2023, or net loss per share of $1.31 basic and diluted.
  • Cash Position: Cash, cash equivalents and restricted cash at March 31, 2024 were approximately $34.9 million, as compared to $41.0 million at December 31, 2023.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva’s goal is to transform the lives of patients with improved therapeutic options, including roluperidone for negative symptoms of schizophrenia and MIN-301 for Parkinson’s disease. For more information, please visit the Company’s website.

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include, but are not limited to, statements herein with respect to expectations concerning Minerva’s ability to remediate or otherwise resolve issues and deficiencies identified in the CRL. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, Minerva’s ability to address FDA’s feedback and timing thereof; uncertainties associated with regulatory processes, including the content and timing of decisions by the FDA; general risks associated with developing biopharmaceutical product candidates; management’s ability to successfully achieve its goals; our ability to raise additional capital to fund its operations and corporate objectives on terms acceptable to Minerva; general economic conditions; and other factors that are described under the caption “Risk Factors” in Minerva’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on February 22, 2024, as updated by its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. Copies of reports filed with the SEC are posted on Minerva’s website at The forward-looking statements in this press release are based on information available to the Company as of the date hereof, and the Company disclaims any obligation to update any forward-looking statements, except as required by law.


Investor inquiries:
Frederick Ahlholm
Chief Financial Officer
Minerva Neurosciences, Inc.

Media inquiries:
Helen Shik
Shik Communications LLC

March 31, 2024December 31, 2023
(in thousands)
Current assets:
Cash and cash equivalents$34,818$40,913
Restricted cash100100
Refundable regulatory fee--
Prepaid expenses and other current assets703989
Total current assets35,62142,002
Equipment and capitalized software, net2029
Total assets$50,510$56,900
Current liabilities:
Accounts payable$1,435$1,805
Accrued expenses and other current liabilities1,3951,535
Total current liabilities2,8303,340
Long-term liabilities:
Liability related to the sale of future royalties84,26782,017
Total liabilities87,09785,357
Stockholders' deficit:
Common stock11
Additional paid-in capital368,796368,357
Accumulated deficit(405,384)(396,815)
Total stockholders' deficit(36,587)(28,457)
Total liabilities and stockholders' deficit$50,510$56,900

Three Months Ended March 31,
(in thousands, except per share amounts)
Operating expenses:
Research and development$         4,167$2,653
General and administrative2,5152,695
Total operating expenses6,6825,348
Loss from operations(6,682)(5,348)
Foreign exchange gains (losses)5(9)
Investment income358364
Non-cash interest expense for the sale of future royalties(2,250)(1,977)
Net loss$(8,569)$(6,970)
Net loss per share, basic and diluted$(1.13)$(1.31)
Weighted average shares outstanding, basic and diluted7,5695,340
To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Prosafe SE: Prosafe issued Conditional Letter of Intent for Safe Boreas30.5.2024 11:08:50 CEST | Press release

Oslo, 30 May 2024 Prosafe has been issued a Conditional Letter of Intent (CLoI) for the Safe Boreas to provide gangway connected operations to support a project off the coast of Western Australia. The CLoI is conditional upon execution of a final contract. The firm duration of the contract linked to the CLoI is 15 months with up to six months of options. The Safe Boreas will mobilise from the North Sea within Q2 2025. Safe Boreas will undergo its five-yearly special periodic survey and other maintenance works prior to commencement of the contract. The value of the contract linked to the CLoI is approximately USD 75 million to USD 100 million depending on options. The Safe Boreas is one of the world’s most advanced and versatile semi-submersible DP-3 accommodation vessels and complies with stringent rules in Australia, Norway and UK. Single person cabins, extensive recreation facilities, combined with a large deck area, cranes and passive motion compensated gangway will ensure the highe

Fortuna publishes its 2023 Sustainability Report30.5.2024 11:00:00 CEST | Press release

VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM | TSX: FVI) is pleased to announce the publication of its sixth annual sustainability report which details the Company’s performance on key environmental, social, and governance (ESG) indicators during 2023. The report also includes dedicated sections on Fortuna’s sustainability management and initiatives at each of the Company’s operating mines as well as the contributions made within the countries that host our operations in the Latin America and West Africa regions. Also included is an ESG data section containing disclosure under sustainability accounting Standards Board (SASB) Metals and Mining Standard, the Task Force on Climate-Related Financial Disclosures Recommendations (TCFD), and the Global Reporting Initiative (GRI) standard. Jorge A. Ganoza, President and CEO of Fortuna, commented, “In 2023, we have made significant progress with respect to tailings management, climate change

Scape Technologies A/S – forløb af ordinær generalforsamling30.5.2024 10:57:49 CEST | pressemeddelelse

Nasdaq First North Growth Market Denmark Selskabsmeddelelse nr. 69/2024 Odense, 30. maj 2024 Scape Technologies A/S – forløb af ordinær generalforsamling Der er i dag afholdt ordinær generalforsamling i Scape Technologies A/S med følgende dagsorden: 1. Valg af dirigent 2. Fremlæggelse af den reviderede årsrapport til godkendelse 3. Beslutning om anvendelse af overskud eller dækning af underskud i henhold til den godkendte årsrapport 4. Valg af medlemmer til bestyrelsen 5. Valg af revisor 6. Eventuelle forslag fra bestyrelse og aktionærer Forslag om afnotering fra Nasdaq First North Growth Market DenmarkForslag om nedsættelse af aktiekapitalen Selskabets aktionærer godkendte årsrapporten og den foreslåede resultatdisponering. Bestyrelsens medlemmer blev genvalgt. Selskabets revisor, Deloitte Statsautoriseret Revisionspartnerskab, blev genvalgt. Generalforsamling godkendte afnotering af selskabets aktier fra Nasdaq First North Growth Market Denmark. Selskabet vil nu anmode Nasdaq First N

Copenhagen Capital A/S – Kapitalnedsættelse30.5.2024 10:36:40 CEST | pressemeddelelse

Selskabet oplyser, at bestyrelsen har truffet beslutning om at gennemføre kapitalnedsættelsen med annullation af nom. kr. 8.684.791 8% præferenceaktier 2024 vedtaget på selskabets generalforsamling den 29. april 2024. Kapitalnedsættelsen er efterfølgende registreret i Erhvervsstyrelsen. Selskabets aktiekapital er herefter i alt nominelt kr. 62.027.010. Aktiekapitalen er opdelt i nominelt kr. 49.019.913 stamaktier og nominelt kr. 13.007.097 40% præferenceaktier 2032. Opdaterede vedtægter vedhæftes. Med venlig hilsen Copenhagen Capital A/S Direktør Rasmus Greis Telefon: +45 70 27 10 60 Email: Vedhæftede filer 20240530 Kapitalnedsættelse20240530 - Vedtægter - Copenhagen Capital AS

HiddenA line styled icon from Orion Icon Library.Eye